Wuxi Biologics (Cayman) (HK:2269) has released an update.
WuXi Biologics (Cayman) Inc. has announced the acquisition of a 30% equity interest in WuXi Vaccines, making it a wholly-owned subsidiary with a purchase price of US$108.5 million. The deal further consolidates the company’s financial results into the group’s statements and is in accordance with the Listing Rules for connected transactions. The acquisition is strategically aimed at enhancing the company’s control and influence over WuXi Vaccines, leveraging its historical performance and future business prospects.
For further insights into HK:2269 stock, check out TipRanks’ Stock Analysis page.
